EpiBiologics

EpiBiologics is a private, preclinical-stage biotech pioneering extracellular targeted protein degradation (TPD). The company's modular EpiTAC platform leverages a novel atlas of over 270 tissue-enriched 'degrader receptors' to design bispecific antibodies that selectively degrade membrane and extracellular proteins in specific cell types. Founded in 2020 and based in San Diego, the company is advancing a pipeline in oncology and immunology, backed by significant venture capital, including a $107M Series B round closed in early 2026. EpiBiologics aims to address the ~40% of the proteome considered inaccessible to traditional TPD approaches.

EpiTAC platform: a modular bispecific antibody system that pairs a target-binding arm with a degrader receptor-binding arm (selected from a proprietary EpiAtlas of 270+ internalizing receptors) to drive tissue-selective degradation of extracellular and membrane proteins via proteasomal (AbTACs) or lysosomal (KineTACs, TrainTACs) pathways.

EpiBiologics competes in the targeted protein degradation space, but with a specific focus on extracellular targets. Key competitors include other biotechs developing lysosome-targeting chimeras (LYTACs), antibody-based degraders, and alternative extracellular degradation platforms. Large pharma companies are also actively exploring this area through internal research and partnerships.